MedPath

NHS Offers CAR T-cell Therapy to Lupus Patients in Groundbreaking Trial

• Three patients in the UK receive CAR T-cell therapy on the NHS in a trial offering potential remission for severe lupus, a disease affecting 70,000 in the UK. • The therapy genetically modifies immune cells to target and attack cells driving lupus inflammation, providing a possible cure where only immunosuppression was available. • Katie Tinkler, a lupus patient for 30 years, expresses hope that the trial's results will offer an endpoint for those with autoimmune diseases, improving their quality of life. • University College London Hospitals NHS Foundation Trust (UCLH) is conducting the trial, marking a significant step forward in treating autoimmune conditions like lupus.

Three patients in the UK have received CAR T-cell therapy through the NHS in a groundbreaking trial that offers a potential remission for severe lupus. This marks a significant advancement in treating the autoimmune disease, which affects approximately 70,000 individuals in the UK. The therapy, administered at University College London Hospitals NHS Foundation Trust (UCLH), modifies cells to enable the body’s immune system to recognize and attack cells driving lupus inflammation.

Patient Perspective

Katie Tinkler, a 50-year-old lupus patient from Guildford, shared her experience with the PA news agency. Diagnosed at 20, Tinkler has endured extreme joint pain, fatigue, antiphospholipid syndrome, focal myositis, and kidney disease. "I started to get extreme joint pain and, in the first few years, that was my main symptom – like excruciating," she said. Her treatment has included steroids and immunosuppressants, but her health has been declining. Tinkler expressed her excitement about the trial, stating, "Up until now, there’s never been anything for lupus that is a possible cure... If this works, it’s life-changing."

Mechanism of CAR T-cell Therapy

CAR T-cell therapy involves genetically modifying a patient's own T cells to target specific cells within their body. In the context of lupus, these modified T cells are engineered to recognize and eliminate the immune cells responsible for causing inflammation and tissue damage. This targeted approach aims to reset the immune system, potentially leading to long-term remission without the need for continuous immunosuppression.

Hope for Autoimmune Diseases

Tinkler hopes the trial will offer hope to others with autoimmune diseases. "There’s so many autoimmune diseases out there... so I hope that the results from this trial come out and it gives people the hope that everybody who has an autoimmune disease will be able to have an end point," she said. She added that until now, treatment has been limited to immunosuppression, which has its own issues. The trial represents a significant step towards finding a potential cure and improving the quality of life for those affected by lupus and other autoimmune conditions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CAR T-cell Therapy Offers Hope for Lupus Patients in UK Clinical Trial

Katie Tinkler, a lupus patient, receives CAR T-cell therapy in a UK clinical trial, marking a potential breakthrough in lupus treatment.
The therapy genetically modifies cells to target and attack cells driving lupus inflammation, offering a possible cure.

CAR T-Cell Therapy Trial Offers Hope for Severe Lupus Patients in the UK

A Phase 1 clinical trial is underway in the UK to assess CAR T-cell therapy for severe lupus, offering a potential alternative to lifelong medication.
The CARLYSE trial, sponsored by Autolus, is the first in the UK to explore CAR T-cell therapy for a non-cancer autoimmune disease.

CAR-T Therapy Shows Promise in Treating Severe Lupus in UK First

A woman in Manchester is the first in the UK to receive CAR-T therapy for severe lupus, an autoimmune condition affecting multiple organs.
The Phase 1 CARLYSE study assesses CAR-T therapy's potential to reduce or eliminate the need for lifelong medication in severe lupus patients.

CAR T-cell Therapy Shows Promise in Treating Severe Lupus in UK Trial

Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune disease.
Early results from a German study showed that patients who underwent CAR T-cell therapy are now in remission and do not require lupus medication.

CAR T-Cell Therapy Shows Promise in Treating Severe Lupus in UK Trial

Three patients in the UK have received CAR T-cell therapy for severe lupus, offering a potential cure and eliminating the need for lifelong medication.
The NHS trial, led by UCLH and UCL, uses genetically modified cells to target and attack problem cells, showing early indications of revolutionizing lupus treatment.

CAR T-cell Therapy Shows Promise in Treating Severe Lupus

Three UK patients have received CAR T-cell therapy for severe lupus, offering hope for a potential cure and eliminating the need for lifelong medication.
The treatment, which modifies the immune system to target problem cells, has shown promising early results, with some patients achieving drug-free remission.

CAR T-Cell Therapy Shows Promise in Treating Severe Lupus in UK Trial

Three patients in the UK have received CAR T-cell therapy for severe lupus, a potentially life-threatening autoimmune condition, in a new NHS trial led by UCLH and UCL.
Early results from a German study indicate that CAR T-cell therapy could induce drug-free remission in lupus patients, offering a possible cure and revolutionizing treatment.

CAR-T Therapy Shows Promise in Treating Lupus and Other Autoimmune Diseases

CAR-T cell therapy has induced drug-free remission in a significant number of lupus patients, offering a potential breakthrough in autoimmune disease treatment.
Biotech companies and large pharmaceutical firms are investing in CAR-T and similar cellular therapies for autoimmune diseases, signaling a shift in treatment strategies.

CAR T-Cell Therapy Shows Promise in Treating Lupus

CAR T-cell therapy has demonstrated promising early results in treating lupus, an autoimmune disease, according to a recent study published in Nature Medicine.
The study involved five young adults with lupus who did not respond to standard treatments, all of whom achieved remission after CAR T-cell therapy.

CAR T-Cell Therapy Induces Remission in Severe Autoimmune Diseases

A pilot study demonstrates that CAR T-cell therapy can induce long-term remission in severe autoimmune diseases, potentially eliminating the need for continuous drug-based therapy.
The therapy involves a single infusion of CAR T-cells, engineered from the patient's own immune cells, to target and eliminate pathogenic B-lymphocytes.

Reference News

[1]
Three patient receive 'groundbreaking' lupus treatment in the UK - The Independent
independent.co.uk · Nov 8, 2024

Three lupus patients in the UK received CAR T-cell therapy, a groundbreaking treatment that could potentially cure the d...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy